Contact Us

Follow

Revolutionizing Healthcare with nsPFA™ Technology

"The technology at Pulse Biosciences shows immense potential for treating a variety of health conditions, particularly atrial fibrillation. Its safety and effectiveness in treating over 6,000 patients is truly exciting. We are honored to bring such revolutionary solutions to the public."

Bob Duggan

Overview

Pulse Biosciences stands at the forefront of biomedical technology as the pioneering inventor and manufacturer of its patented Nanosecond Pulsed Field Ablation™ (nsPFA™) technology. Harnessing the unique potential of nsPFA, the company is committed to addressing high-impact areas in healthcare, with a current focus on cardiology applications.

Pulse Biosciences is investigating a variety of applications for its technology, including immuno‐oncology, dermatology, and veterinary medicine.

Technology

Pioneering Work in Nanosecond Pulsed Field Ablation

The core technology that underpins Pulse Biosciences is the innovative nsPFA. It serves as a powerful tool that can nonthermally clear cells, while sparing adjacent noncellular tissue. This technology delivers nanosecond pulses of electrical energy, with pulse durations ranging from billionths to a millionth of a second.

The nsPFA energy is dispensed through the robust and adaptable nsPFA™ generator platform. This technology has been meticulously designed to connect to various types of applicators, from superficial to surgical to catheter-based therapies, making it a flexible solution for different healthcare applications.

Pulse Biosciences’ nsPFA technology is not merely theoretical; it’s already been used to treat over 6,000 patients safely and effectively outside of Cardiology. This proves the practicality and effectiveness of the technology across a multitude of therapy areas.

The Power and Potential of nsPFA Technology

When the nsPFA energy pulses are applied to targeted tissue, they enter cells and alter the function of the internal cellular organelles, including the mitochondria and endoplasmic reticulum. This causes a cascade of intracellular disruption that eventually leads to regulated cell death (RCD), a process that occurs when cells in the human body experience stress and cannot restore cellular homeostasis.

Interestingly, the nsPFA technology has shown immense promise in the cardiology field, where it is being explored as a potential treatment for atrial fibrillation. However, the potential applications of this novel technology extend far beyond cardiology, offering hope to patients across a broad spectrum of therapy areas.

Proprietary Technology and Unrivaled Expertise

Pulse Biosciences holds exclusive rights to the nsPFA technology, making it a sole proprietor in this cutting-edge field. The team at Pulse Biosciences consists of top experts in pulsed electric field technologies and possesses wide-ranging engineering expertise across multiple medical device domains.

The company’s commitment to health innovation is clear. By leveraging their unique nsPFA™ technology, they aim to address a variety of applications where optimal solutions remain elusive, thereby fulfilling their mission to improve and extend the lives of patients.

An Expansive Intellectual Property Portfolio

With over 130 issued patents globally owned and licensed, Pulse Biosciences’ intellectual property (IP) portfolio is both deep and broad. This growing patent portfolio not only safeguards their pioneering nsPFA technology but also facilitates the development of a rich pipeline of transformative commercial applications.

The company is resolute in realizing the immense potential of their Nanosecond Pulsed Field Ablation technology. Through their unwavering commitment to innovation and dedication to improving patient lives, Pulse Biosciences is truly revolutionizing the field of healthcare.

Key Dates

Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

18 May 2023

Go to link

Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results

11 May 2023

Go to link

Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer

10 May 2023

Go to link

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

10 May 2023

Go to link

Pulse Biosciences Announces $65 Million Private Placement

01 May 2023

Go to link

Presentation of clinical studies data to clear skin lesions at ASDS annual meeting

17 Oct 2019

Go to link

Promising non-thermal treatment for skin conditions

18 Sep 2019

Go to link

Pulse Biosciences CellFX™ system to be given podium presentation at major Aesthetic Procedures conference

06 Aug 2019

Go to link

Publication of dose-response study using PulseX system

02 Aug 2019

Go to link

Research program explores energy for lesion treatment

14 May 2019

Go to link

Presentations announced at 2019 American Society for Laser Medicine and Surgery annual conference

26 Mar 2019

Go to link

510(K) for CellFX™ submitted to FDA

28 Jan 2019

Go to link

Positive clinical results of Nano-Pulse Stimulation to treat patients with Sebaceous Hyperplasia Lesions on the face

07 Jan 2019

Go to link

Continued expansion of its clinical study programs in dermatology

11 Oct 2018

Go to link

Treats initial patient in its human study evaluating the effects of Nano-Pulse Stimulation in Basal Cell Carcinoma

30 Jul 2018

Go to link

ODU researchers are using electric pulses to kill cancer cells. And they say it’s working.

27 Jun 2018

Go to link

Positive results from its first study evaluating a clinical target at major scientific meeting

12 Apr 2018

Go to link

Bob Duggan has been appointed Chairman of the Board; Ken Clark, Dr. Thomas Fogarty and Manmeet S. Soni have been appointed as independent directors

02 Nov 2017

Go to link

Pulse Biosciences announces $30 million private placement

23 Sep 2017

Go to link

Withdrawal and resubmission of 510(K) application for PulseTx™ System

11 Sep 2017

Go to link

Treatment of first patient in study to evaluate Novel Nano-Pulse Stimulation for Seborrheic Keratosis Lesions

06 Jun 2017

Go to link

Pulse Biosciences submits 510(K)Application to FDA for PULSEX™ system

14 Mar 2017

Go to link

Bob Duggan and Dr. Maky Zanganeh acquire combined interest of 17.1% of Pulse Biosciences

09 Feb 2017

Go to link

Media

Pulse Biosciences Reports Third Quarter 2022 Financial Results

10 Nov 2023

Go to link

Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023

27 Apr 2023

Go to link

Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results

30 Mar 2023

Go to link

PULSE BIOSCIENCES ANNOUNCES ITS NOVEL NANOSECOND PULSED FIELD ABLATION SYSTEM WILL BE HIGHLIGHTED AT THE 2023 AF SYMPOSIUM

02 Feb 2023

Go to link

Emerging technology: a look at nano-pulse stimulation

19 Aug 2020

Go to link

Nano-pulse stimulation technology produces favorable results in several clinical studies presented at the 2020 ASLMS virtual annual conference

09 Jul 2020

Go to link

Pulse Biosciences, Inc.’s nano-pulse stimulation technology produces favorable results for warts and all

07 Jul 2020

Go to link

High amplitude electromagnetic fields: a new player in dermatology

06 Jul 2020

Go to link

New device treats nonmelanoma skin cancer

04 Jun 2020

Go to link

Pulse plans to seek $30m from investors

07 Apr 2020

Go to link

Decrease in the number of active acne lesions on the back 3 months after a single nano-pulse stimulation treatment —Mark S. Nestor, MD, PhD

25 Oct 2019

Go to link

This first human study of the treatment describes the use of nanosecond pulsed electric fields (nsPEF) on the skin

18 Sep 2019

Go to link

Nano-pulse stimulation represents novel technology for delivering cellular specific therapy that is being investigated for its potential to treat both benign and malignant dermatological lesions

14 May 2019

Go to link

"This is an incredibly exciting technology...There’s a whole world, both cosmetic and clinical, including skin cancer that’s going to be looked at continually as we go forward."

Mark S. Nestor

MD, PhD

Key Dates

Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

18 May 2023

Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results

11 May 2023

Pulse Biosciences, Inc. Appoints Dr. Gan Dunnington as Chief Medical Officer

10 May 2023

Pulse Biosciences, Inc. Announces Planned Redemption of Warrants

10 May 2023

Pulse Biosciences Announces $65 Million Private Placement

01 May 2023

Presentation of clinical studies data to clear skin lesions at ASDS annual meeting

17 Oct 2019

Promising non-thermal treatment for skin conditions

18 Sep 2019

Pulse Biosciences CellFX™ system to be given podium presentation at major Aesthetic Procedures conference

06 Aug 2019

Publication of dose-response study using PulseX system

02 Aug 2019

Research program explores energy for lesion treatment

14 May 2019

Presentations announced at 2019 American Society for Laser Medicine and Surgery annual conference

26 Mar 2019

510(K) for CellFX™ submitted to FDA

28 Jan 2019

Positive clinical results of Nano-Pulse Stimulation to treat patients with Sebaceous Hyperplasia Lesions on the face

07 Jan 2019

Continued expansion of its clinical study programs in dermatology

11 Oct 2018

Treats initial patient in its human study evaluating the effects of Nano-Pulse Stimulation in Basal Cell Carcinoma

30 Jul 2018

ODU researchers are using electric pulses to kill cancer cells. And they say it’s working.

27 Jun 2018

Positive results from its first study evaluating a clinical target at major scientific meeting

12 Apr 2018

Bob Duggan has been appointed Chairman of the Board; Ken Clark, Dr. Thomas Fogarty and Manmeet S. Soni have been appointed as independent directors

02 Nov 2017

Pulse Biosciences announces $30 million private placement

23 Sep 2017

Withdrawal and resubmission of 510(K) application for PulseTx™ System

11 Sep 2017

Treatment of first patient in study to evaluate Novel Nano-Pulse Stimulation for Seborrheic Keratosis Lesions

06 Jun 2017

Pulse Biosciences submits 510(K)Application to FDA for PULSEX™ system

14 Mar 2017

Bob Duggan and Dr. Maky Zanganeh acquire combined interest of 17.1% of Pulse Biosciences

09 Feb 2017

Media

Pulse Biosciences Reports Third Quarter 2022 Financial Results

10 Nov 2023

Pulse Biosciences Schedules First Quarter 2023 Financial Results Conference Call for May 11, 2023

27 Apr 2023

Pulse Biosciences Reports Fourth Quarter & Full Year 2022 Financial Results

30 Mar 2023

PULSE BIOSCIENCES ANNOUNCES ITS NOVEL NANOSECOND PULSED FIELD ABLATION SYSTEM WILL BE HIGHLIGHTED AT THE 2023 AF SYMPOSIUM

02 Feb 2023

Emerging technology: a look at nano-pulse stimulation

19 Aug 2020

Nano-pulse stimulation technology produces favorable results in several clinical studies presented at the 2020 ASLMS virtual annual conference

09 Jul 2020

Pulse Biosciences, Inc.’s nano-pulse stimulation technology produces favorable results for warts and all

07 Jul 2020

High amplitude electromagnetic fields: a new player in dermatology

06 Jul 2020

New device treats nonmelanoma skin cancer

04 Jun 2020

Pulse plans to seek $30m from investors

07 Apr 2020

Decrease in the number of active acne lesions on the back 3 months after a single nano-pulse stimulation treatment —Mark S. Nestor, MD, PhD

25 Oct 2019

This first human study of the treatment describes the use of nanosecond pulsed electric fields (nsPEF) on the skin

18 Sep 2019

Nano-pulse stimulation represents novel technology for delivering cellular specific therapy that is being investigated for its potential to treat both benign and malignant dermatological lesions

14 May 2019